New drug combo aims to control lymphoma without chemo
NCT ID NCT04883437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of two drugs, acalabrutinib and obinutuzumab, in people with untreated follicular lymphoma or other slow-growing non-Hodgkin lymphomas. The goal is to see if this drug pair can shrink tumors and control the disease. About 49 participants will receive the drugs, and researchers will monitor how well the cancer responds and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- acalabrutinib and obinutuzumab
- What this could lead to
- If this works, it could offer a new, effective treatment option for people with untreated follicular lymphoma, potentially controlling the disease without chemotherapy.
- What could go wrong
- This is an early phase 2 trial with only 49 participants. The combination may cause side effects, and it's not yet known if it works better than standard treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 1 FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a new tracer light up cancer growth?
- Can two immune boosters outsmart follicular lymphoma without chemo?